Tech giant Amazon is reportedly working with the Fred Hutchinson Cancer Center in Seattle to develop a cancer vaccine and is already recruiting for clinical trials.
Business Insider reports that an internal Amazon team has developed a cancer vaccine in partnership with the Fred Hutchinson Cancer Center in Seattle. The project is reportedly already recruiting patients for an FDA-approved clinical trial.
MICHEL DANIO/AFP/Getty Images
Jeff Bezos/Instagram
The clinical trial reportedly aims to develop personalized vaccines to treat breast cancer and a skin cancer known as melanoma. The vaccine will offer personalized cancer treatment at an affordable price and will be an alternative to chemotherapy if trials are successful.
An abstract published on Clinicaltrials.gov says the project was first shared with Amazon and Fred Hutchinson at the end of October. The start date of the study is planned as 9 June 2022, and the estimated completion date is 1 November 2023. The study is currently in the early stages of Phase 1 and has enrolled 20 patients over the age of 18 for the “US FDA”. testing. -regulated medicinal product”, according to the summary page.
Fred Hutchinson is listed as a trial sponsor, and Amazon is an “employee” in the study. The summary page also states that “a personalized neoantigen peptide vaccine” should be tested for safety for advanced melanoma and “Her2-negative hormone receptor positive breast cancer” resistant to other treatments.
An Amazon spokesperson confirmed to Business Insider that Ferd Hutchinson is leading the case. Representative said:
Amazon is contributing scientific research and machine learning experiences in partnership with Fred Hatch to explore the development of personalized treatments for specific types of cancer. It’s too early, but Fred Hutch has recently received approval from the U.S. Food and Drug Administration to run a phase I clinical trial, and it’s not yet clear whether it will be successful.
It will be a process that will take many years – if it develops, we will be open to collaborations with other organizations in the health and life sciences that may be interested in similar efforts.
Read more about Business Insider here.
Source: Breitbart
